Drug Profile
Ragweed allergy vaccine - NIOX
Latest Information Update: 29 Jun 2023
Price :
$50
*
At a glance
- Originator Circassia
- Developer NIOX
- Class Allergens; Antiallergics; Peptide vaccines; Peptides; Plant allergy immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Seasonal allergic rhinitis
Most Recent Events
- 25 Jun 2015 Phase-II development is ongoing for Seasonal allergic rhinitis in Canada
- 01 Oct 2014 Circassia completes a phase II trial in Seasonal allergic rhinitis in Canada (NCT02061709)
- 01 Jan 2014 Circassia initiates enrolment in a phase II trial for Seasonal allergic rhinitis in Canada (NCT02061670)